EXAI Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 106989 min ago

@ $5.91

Wydano: 14 vas. 2024 @ 22:27

Zwrot: -31.81%

Poprzedni sygnał: vas. 14 - 17:17

Poprzedni sygnał: Sprzedaż

Zwrot: -2.24 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	384 502
Średni wolumen	732 390
Kapitalizacja rynkowa	506.58M
EPS	$0 ( 2024-03-28 )
Następna data zysków	( $-0.370 ) 2024-05-22
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.74
ATR14	$0.00600 (0.15%)

Wolumen Korelacja

Długi: 0.34 (neutral)

Krótki: 0.34 (neutral)

Signal:(54.919) Neutral

Exscientia plc Korelacja

10 Najbardziej pozytywne korelacje
TLGT	0.858
VINC	0.855
SVAC	0.848
EVOK	0.846
IMUX	0.82
FEYE	0.816
RMRM	0.816
ANGI	0.809
MKSI	0.805

10 Najbardziej negatywne korelacje
AMRB	-0.894
MMAC	-0.841
JCOM	-0.832
NETE	-0.82
GOODM	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Exscientia plc Korelacja - Waluta/Towar

0.75
( moderate )

0.49
( neutral )

0.00
( neutral )

0.58
( weak )

0.00
( neutral )

-0.18
( neutral )

Exscientia plc Finanse

Annual	2023
Przychody:	$24.96M
Zysk brutto:	$-28.48M (-114.12 %)
EPS:	$-1.460

FY	2023
Przychody:	$24.96M
Zysk brutto:	$-28.48M (-114.12 %)
EPS:	$-1.460

FY	2022
Przychody:	$32.90M
Zysk brutto:	$-7.30M (-22.19 %)
EPS:	$-1.170

Financial Reports:

No articles found.

Exscientia plc

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.